Executive Director, Clinical Development

Company Overview

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.

Position Overview

The Executive Director, Clinical Development will serve as a key member of Immunome’s R&D leadership team, reporting to the Chief Medical Officer. This executive will provide strategic direction and oversight for the clinical development of Immunome’s pipeline, advancing innovative targeted oncology programs from early development through late-stage trials. The VP will play a critical role in shaping portfolio strategy, leading global clinical trial execution, and representing Immunome with regulators, investigators, and external stakeholders.

Responsibilities

• Provide strategic clinical leadership and hold responsibility for all clinical deliverables.
• Development of protocols consistent with the Clinical Development Plans (CDP), clinical components of regulatory documents and brand related medical information, clinical communication, and publications.
• Manage operational aspects and drive execution of the clinical program in partnership with other line functions.
• Manage budget and resources in coordination with CMO, and Project Managers, ensuring timely execution of assigned clinical deliverables.
• Participate in/contribute to activities with external stakeholders (e.g., regulatory authorities, key opinion leaders, advisory boards, patient advocacy groups), internal stakeholders, Translational Medicine, etc.) and internal decision boards.
• Develop and maintain strong relationships with both internal and external scientific experts in order to represent the company’s interests from a clinical perspective.
• Support the CMO in ensuring overall safety of the compound in collaboration with the Safety Leader for the assigned program section.
• Remain current with clinical and drug development information relevant to assigned programs through the review of literature and attendance at medical/scientific meetings.
• Lead development and ensure implementation across program specific standards.

Qualifications

• M.D. with clinical research experience in oncology products is required.
• A minimum of 10+ years of clinical development experience in oncology.
• Proven track record of advancing oncology programs through pivotal/registrational trials; prior leadership experience in large pharma or biotech strongly preferred.

Knowledge and Skills

• Deep expertise in oncology clinical trial design and execution, including early- and late-stage studies
• Thorough knowledge of FDA, EMA, and ICH regulations and guidance for oncology drug development; proven ability to lead regulatory interactions globally.
• Proven ability to design, run, and analyze global clinical studies,
• Strong understanding of translational medicine, clinical pharmacology, and the integration of biomarker insights into clinical development strategy.

E/E/O

Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.